The four-person panel, including John Heymach, MD, PhD, from MD Anderson Cancer Center, discuss the current FDA-approved targeted treatments for RET-positive lung cancer—selpercatinib (Retevmo) and pralsetinib (Gavreto). While these first-line treatments have proven helpful in treating RET-positive non-small cell lung cancer, the cancer cells can eventually become resistant to the treatment, which is guiding much of Dr. Heymach’s attention at the moment.
Watch the full video to hear about:
- Dr. Heymach’s research on targeting resister cells
- How patients and advocacy groups can support research into RET-positive lung cancer
- Differences between “on target” and “off target” mutations
- Differences between a RET mutation and RET fusion
- Targeted therapy vs immunotherapy for treating RET-positive lung cancer
- The importance of patients sharing their experiences with drug side effects